StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Stifel Reiterates Hold Rating on ResMed (RMD), but Raises Estimates
March 16, 2026 7:46 AM
Stifel analyst Jonathan Block reiterated a Hold rating and $265.00 price target on ResMed (NYSE: RMD).The analyst commented, "Our proprietary ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
